超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Eutropics   
開發了一種新的試驗，以指導癌癥治療BH3分析生物標志物采用專有技術，以取代目前的治療模式，提供更有針對性的治療。

Eutropics Pharmaceuticals develops a novel test to guide cancer treatment by employing proprietary BH3-profiling biomarker technology to replace current treatment paradigms with more targeted therapy. The biomarker provides a unique understanding of cancer cells that will be important in the clinical stages of development and in guiding the use of marketed cancer drugs. The BH3 profiling assay also provides a biomarker that is important in the pre-clinical development of experimental drugs, including the company’s first in class anti-cancer therapeutic lead compound.

Cancer cells survive due to blocks that prevent apoptosis: the drugs Eutropics Pharmaceuticals is developing trigger cell death in cancer cells that otherwise elude control.

A unique and powerful assay guides clinicians in the use of the drugs. The assay establishes where apoptosis is blocked and what specific protein is the cause. This tells clinicians in advance which patients will respond to ours and current therapeutics.

Disease targets include blood cancers, small cell lung cancers and ovarian cancer.